摘要
目的探讨美罗培南联合孟鲁司特钠对儿童细菌性支气管炎的治疗效果及对血清C-反应蛋白(CRP)、白细胞(WBC)水平的影响。方法选取2016年2月至2017年2月接受治疗的细菌性支气管炎患儿200例,随机分为孟鲁司特钠组和联合用药组,每组100例,孟鲁司特钠组患儿使用孟鲁司特钠治疗,联合用药组患儿在孟鲁司特钠组基础上使用美罗培南联合治疗。免疫透射比浊法检测CRP水平,全自动血液细胞分析仪检测血清WBC水平,肺功能仪检测1 s用力呼气容积(FEV1)、用力肺活量(FVC)水平,比较2组患儿临床症状消失时间、住院时间、疗效及不良反应发生情况。结果2组患儿治疗前CRP、WBC水平差异无统计学意义(P>0.05);治疗后2组患儿CRP、WBC水平均低于治疗前,且联合用药组患儿治疗后CRP、WBC水平均明显低于孟鲁司特钠组,差异均有统计学意义(P<0.05)。2组患儿治疗前FEV1、FVC水平差异无统计学意义(P>0.05);治疗后2组患儿FEV1、FVC水平均高于治疗前,且联合用药组患儿治疗后FEV1、FVC水平均明显高于孟鲁司特钠组,差异均有统计学意义(P<0.05)。联合用药组患儿喘息消失时间、体温恢复时间、咳嗽消失时间以及住院时间均明显低于孟鲁司特钠组,差异均有统计学意义(P<0.05)。联合用药组患儿治疗的总有效率达98.00%显著高于孟鲁司特钠组的86.00%,差异有统计学意义(P<0.05)。联合用药组患儿不良反应发生率为2.00%明显低于孟鲁司特钠组的9.00%差异有统计学意义(P<0.05)。结论美罗培南联合孟鲁司特钠治疗儿童细菌性支气管炎症状效果显著,能有效调控患儿血清CRP、WBC水平,且不良反应发生率较低。
Objective To investigate the therapeutic effects of meropenem combined with montelukast on bacterial bronchitis in children and their effects on C reactive protein(CRP)and white blood cell(WBC)levels.Methods Two hundred children patients with bacterial bronchitis who were treated in our hospital from February 2016 to February 2017 were randomly divided into montelukast treatment group(n=100)and combination treatment group(n=100).The patients in montelukast treatment group were treated by montelukast only,however,the patients in combination treatment group were treated by meropenem combined with montelukast.The CRP levels were detected by immunoturbidimetry,and the serum levels of WBC were detected by automatic hematology analyzer.The levels of forced expiratory volume(FEV1)and forced vital capacity were measured by lung function instrument.The time of disappearance of clinical symptoms,hospitalization time,the therapeutic effects and the incidence of adverse reactions were observed and compared between the two groups.Results After treatment,the levels of CRP and WBC in combination treatment group were significantly lower than those in montelukast treatment group(P<0.05).The levels of FEV1 and FVC in combination treatment group were significantly higher than those in montelukast treatment group(P<0.05).The time of disappearance of wheezing,the time of body temperature recovery,the time of disappearance of cough and hospitalization time in combination treatment group were significantly lower than those in montelukast treatment group(P<0.05).Moreover the total effective rate in combination treatment group was significantly higher than that in montelukast treatment group(P<0.05),however,the incidence rate of adverse reactions in combination treatment group was significantly lower than that in montelukast treatment group(P<0.05).Conclusion Meropenem combined with montelukast is effective in treatment of bacterial bronchitis in children,whch can effectively regulate the serum levels of CRP and WBC,with lower incidence rate of adverse reactions.
作者
陶喜忠
曹艳秋
TAO Xizhong;CAO Yanqiu(Department of Respiratory Diseases,Jinzhou Hospital for Women and Children,Liaoning,Jinzhou 121000,China)
出处
《河北医药》
CAS
2020年第1期42-45,共4页
Hebei Medical Journal
